ARCHIVES

Three Organizations Publish Guideline For Biomarker Testing for Targeted Therapies

This article is from The Cancer Letter archive.

Vol. 36 No. 4 | April 26, 2013

Download PDF Visit The Full Archive

Related Articles

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

Cancer Letter Office Moves To Capitol Hill; No Issues Published Next Two Weeks

September 1, 1989

FDA Adopts Final Diagnostics X-Ray Rule Amendment

September 9, 1977

DeVita Appointment Now Official; Calls For New Chemoprevention Program, More Applied Prevention

July 18, 1980

Two Phase III Afatinib Trials Demonstrate Prolonged Survival

May 30, 2014

Upton Briefed On Problems; To Start July 25

July 15, 1977